Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanying Du

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Translational Research : the Journal of Laboratory and Clinical Medicine|April 30, 2022
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challengeJuan Shi, Jian Zheng, Xiujuan Zhang, et al.
The Journal of Infectious Diseases|July 13, 2015
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionRudragouda Channappanavar, Lu Lu, Shuai Xia, et al.
The Journal of Infectious Diseases|July 23, 2013
Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodiesLanying Du, Ye Li, Guangyu Zhao, et al.
Molecules (Basel, Switzerland)|March 24, 2019
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-LifeShan Su, Giselle Rasquinha, Lanying Du, et al.
Cellular & Molecular Immunology|March 24, 2020
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineWanbo Tai, Lei He, Xiujuan Zhang, et al.
Scientific Reports|March 3, 2017
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude miceChenglai Xia, Ruihong Chen, Jinman Chen, et al.
Microbes and Infection|May 11, 2020
Current development of COVID-19 diagnostics, vaccines and therapeuticsNaru Zhang, Chaoqun Li, Yue Hu, et al.
Vaccines|April 23, 2025
Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoVXiaoqing Guan, Abhishek K Verma, Qian Liu, et al.
Bioscience Trends|July 10, 2013
A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responsesYe Li, Lanying Du, Hongjie Qiu, et al.
Vaccine|August 5, 2008
Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccinesWenjun Xiao, Lanying Du, Chao Liang, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Translational Research : the Journal of Laboratory and Clinical Medicine|April 30, 2022
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challengeJuan Shi, Jian Zheng, Xiujuan Zhang, et al.
The Journal of Infectious Diseases|July 13, 2015
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionRudragouda Channappanavar, Lu Lu, Shuai Xia, et al.
The Journal of Infectious Diseases|July 23, 2013
Highly pathogenic avian influenza A(H5N1) mutants transmissible by air are susceptible to human and animal neutralizing antibodiesLanying Du, Ye Li, Guangyu Zhao, et al.
Molecules (Basel, Switzerland)|March 24, 2019
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-LifeShan Su, Giselle Rasquinha, Lanying Du, et al.
Cellular & Molecular Immunology|March 24, 2020
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineWanbo Tai, Lei He, Xiujuan Zhang, et al.
Scientific Reports|March 3, 2017
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude miceChenglai Xia, Ruihong Chen, Jinman Chen, et al.
Microbes and Infection|May 11, 2020
Current development of COVID-19 diagnostics, vaccines and therapeuticsNaru Zhang, Chaoqun Li, Yue Hu, et al.
Vaccines|April 23, 2025
Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoVXiaoqing Guan, Abhishek K Verma, Qian Liu, et al.
Bioscience Trends|July 10, 2013
A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responsesYe Li, Lanying Du, Hongjie Qiu, et al.
Vaccine|August 5, 2008
Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccinesWenjun Xiao, Lanying Du, Chao Liang, et al.
Pageof 19